Highlight from recent cancer literature

摘要：

TH-302,a novel tumor hypoxia-selective treatment for patients with cancer Tumor hypoxia has been shown to correlate with poor clinical prognosis due to both therapeutic treatment failure and hypoxia-induced prometastatic potential.A team of researchers from Threshold Pharmaceuticals have demonstrated that TH-302,an optimized hypoxiaactivated prodrug,selectively targets the hypoxic regions of human xenograft tumors.”Targeting tumor hypoxia is an attractive strategy for the development of new and effective cancer therapies,” says Jessica Difei Sun,the senior author of this study.

机标关键词：treatment failure

所属期刊栏目：31

分类号：R75;R74

在线出版日期：2013-09-04（万方平台首次上网日期，不代表论文的发表时间）

页数：共2页

页码：167-168